Resolving a deficiency notice from Nasdaq is a significant positive development for any listed company. It removes the immediate threat of delisting, which can severely impact stock price and investor confidence. For Protagenic Therapeutics, this resolution likely signals to investors that the company has met Nasdaq's listing requirements, potentially leading to positive sentiment and an increase in stock price in the short term.